Literature DB >> 9511070

Provisional interpretive criteria for quinupristin/dalfopristin susceptibility tests.

A L Barry1, P C Fuchs, S D Brown.   

Abstract

For testing bacterial susceptibility to the streptogramin quinupristin/dalfopristin, it seems reasonable that the test reagent should contain a similar ratio of the two compounds as in the therapeutic material, i.e. 30% quinupristin and 70% dalfopristin. The precise ratio of quinupristin to dalfopristin is not critical as long as threshold concentrations of both drugs are present. In-vitro tests were not altered by minor changes in pH, incubation in CO2 or by addition of lysed horse blood to the medium. Filter paper discs containing 15 micrograms of the quinupristin/dalfopristin reagent are preferred for agar diffusion susceptibility testing in order to optimize disc tests with enterococci. Provisional interpretive criteria for pathogens not requiring blood or increased CO2 are: susceptible, inhibition zone diameters of > or = 19 mm or MIC < or = 1.0 mg/L; intermediate, 16-18 mm or MIC 2.0 mg/L; resistant, < or = 15 mm or MIC > or = 4.0 mg/L. Those criteria will need to be reassessed as clinical experiences become available. Of particular concern is the role of quinupristin/dalfopristin in the treatment of infections due to Haemophilus influenzae or Enterococcus faecalis: the clinically relevant interpretive category for each of those two species is yet to be determined.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9511070     DOI: 10.1093/jac/39.suppl_1.87

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  10 in total

1.  Distribution of genes encoding resistance to macrolides, lincosamides, and streptogramins among staphylococci.

Authors:  G Lina; A Quaglia; M E Reverdy; R Leclercq; F Vandenesch; J Etienne
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

Review 2.  Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.

Authors:  H M Lamb; D P Figgitt; D Faulds
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

3.  Provisional quality control parameters and interpretive criteria for testing susceptibility of Streptococcus pneumoniae and Haemophilus influenzae to quinupristin/dalfopristin (RP59500). Antimicrobial Testing Quality Control Group.

Authors:  P Fuchs; A Barry; S Brown
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-03       Impact factor: 3.267

4.  In vitro susceptibilities of aerobic and facultative non-spore-forming gram-positive bacilli to HMR 3647 (RU 66647) and 14 other antimicrobials.

Authors:  F Soriano; R Fernández-Roblas; R Calvo; G García-Calvo
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

5.  Characterization of vancomycin-resistant Enterococcus faecium isolates from the United States and their susceptibility in vitro to dalfopristin-quinupristin.

Authors:  G M Eliopoulos; C B Wennersten; H S Gold; T Schülin; M Souli; M G Farris; S Cerwinka; H L Nadler; M Dowzicky; G H Talbot; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

6.  Effects of genes encoding resistance to streptogramins A and B on the activity of quinupristin-dalfopristin against Enterococcus faecium.

Authors:  B Bozdogan; R Leclercq
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

7.  Pharmacodynamic analysis of the activity of quinupristin-dalfopristin against vancomycin-resistant Enterococcus faecium with differing MBCs via time-kill-curve and postantibiotic effect methods.

Authors:  J R Aeschlimann; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

Review 8.  Streptogramins and their potential role in geriatric medicine.

Authors:  B M Lomaestro; L L Briceland
Journal:  Drugs Aging       Date:  1998-12       Impact factor: 3.923

9.  In vitro activity of quinupristin/dalfopristin against erythromycin-susceptible and erythromycin-resistant Streptococcus pneumoniae.

Authors:  R R Reinert; M Kresken; V Mechery; M Lemperle; R Lütticken
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-09       Impact factor: 3.267

10.  Quinupristin-Dalfopristin.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-12       Impact factor: 3.663

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.